Healthcare / Medical DevicesShenzhen
$31.57
+2.51 (+8.64%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $38.0M · quality 64.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
46/100
C
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.2B
P/E
N/A
•EV/EBITDA
203.1x
↑ROE
-1.8%
↓Gross Margin
48.6%
↑Debt/Equity
0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-4.3%
FCF CAGR
+23.3%
FCF margin
9.8%
FCF / Net income
-1.00x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $387.5M · net income $-37.9M · FCF $38.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $387.5M | $387.5M | $435.5M | $433.7M | $442.1M |
| Net Income | $-37.9M | $-37.9M | $97.4M | $97.2M | $102.5M |
| EBITDA | $15.7M | $15.7M | $158.1M | $156.5M | $156.3M |
| EPS | -0.38 | -0.38 | 0.98 | 0.97 | 1.33 |
| Gross Margin | 48.6% | 48.6% | 49.4% | 48.3% | 52.3% |
| Operating Margin | 14.0% | 14.0% | 19.4% | 20.4% | 26.1% |
| Net Margin | -9.8% | -9.8% | 22.4% | 22.4% | 23.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.05 | 0.05 | 0.02 | 0.00 | 0.00 |
| Current Ratio | 6.74 | 6.74 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $38.0M | $38.0M | $10.5M | $51.7M | $20.3M |
| Returns | |||||
| ROE | -1.8% | -1.8% | 4.3% | 4.3% | 4.7% |
| Valuation | |||||
| P/E | — | — | 22.46 | 28.09 | 28.57 |
| EV/EBITDA | 203.15 | 203.15 | 12.20 | 13.83 | 11.64 |
| P/B | 1.47 | 1.47 | 0.97 | 1.22 | 1.34 |
| Growth & Yield | |||||
| Revenue Growth | -11.0% | -11.0% | 0.4% | -1.9% | — |
| EPS Growth | -138.8% | -138.8% | 1.0% | -27.1% | — |
| Dividend Yield | 1.8% | 1.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+34.8%
Start / end P/E
n/dx → n/dx
EPS bridge
0.98 → -0.38
Residual
+33.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.